These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 24740322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
    Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y.
    Oncotarget; 2014 Mar 30; 5(6):1646-56. PubMed ID: 24722067
    [Abstract] [Full Text] [Related]

  • 5. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C.
    Eur Urol; 2017 Nov 30; 72(5):835-844. PubMed ID: 28528814
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y, Tam T, Jian K, Andersen RJ, Sadar MD.
    Mol Oncol; 2020 Oct 30; 14(10):2455-2470. PubMed ID: 32734688
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
    JAMA Oncol; 2015 Aug 30; 1(5):582-91. PubMed ID: 26181238
    [Abstract] [Full Text] [Related]

  • 9. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
    Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Gjörloff Wingren A, Mongan NP, Heery DM, Johnsson H, Abrahamsson PA, Dizeyi N, Luo J, Persson JL.
    Oncotarget; 2016 Sep 27; 7(39):63065-63081. PubMed ID: 27588408
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.
    Clin Cancer Res; 2015 Apr 01; 21(7):1675-87. PubMed ID: 25634993
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L, Tien JC, Vo J, Tan M, Parolia A, Zhang Y, Wang L, Qiao Y, Shukla S, Wang X, Zheng H, Su F, Jing X, Luo E, Delekta A, Juckette KM, Xu A, Cao X, Alva AS, Kim Y, MacLeod AR, Chinnaiyan AM.
    Cancer Res; 2018 Oct 15; 78(20):5731-5740. PubMed ID: 30135193
    [Abstract] [Full Text] [Related]

  • 16. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC.
    Oncogene; 2021 Sep 15; 40(35):5379-5392. PubMed ID: 34272475
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM.
    Neoplasia; 2020 Feb 15; 22(2):111-119. PubMed ID: 31931431
    [Abstract] [Full Text] [Related]

  • 19. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.
    J Clin Oncol; 2017 Jul 01; 35(19):2149-2156. PubMed ID: 28384066
    [Abstract] [Full Text] [Related]

  • 20. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
    Wu H, You L, Li Y, Zhao Z, Shi G, Chen Z, Wang Z, Li X, Du S, Ye W, Gao X, Duan J, Cheng Y, Tao W, Bian J, Zhou JR, Zhu Q, Yang Y.
    Cancer Res; 2020 Jul 01; 80(13):2927-2939. PubMed ID: 32341037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.